Metastasis-associated tumor antigen 1 (MTA1), a component of the nucleosome remodeling and deacetylating (NuRD) complex is routinely upregulated in several cancers. In the present study, we investigated the potential role of MTA1 in BRCA1 transcriptional repression and subsequent chromosomal instability. MTA1-NuRD complex was found to negatively regulate BRCA1 transcription by physically associating with an atypical estrogen-responsive element (ERE) on the BRCA1 promoter. Moreover, MTA1 and HDAC complex recruited to the ERE of BRCA1 promoter in an ER a-dependent manner. Accordingly, BRCA1 protein levels were enhanced by silencing of either MTA1 expression or by treatment with the specific histone deacetylase inhibitor trichostatin A. MTA1's strong repressive effects on BRCA1 expression was supported by our observation that cells stably overexpressing MTA1 showed centrosome amplification which has been long implicated as a phenotype for BRCA1 repression. Accordingly, overexpression of BRCA1 in cells stably over expressing MTA1 resulted in restoration of normal centrosome numbers. Together, these findings strongly implicate MTA1 in the transcriptional repression of BRCA1 leading to abnormal centrosome number and chromosomal instability.
Introduction
Metastasis tumor antigen 1 (MTA1), a candidate member of the metastasis-associated gene family, is a component of the nucleosome remodeling and deacetylating (NuRD) complex. The NuRD complex has been implicated in adenosine triphosphate-dependent chromatin remodeling and transcriptional regulation. As a part of the NuRD complex, MTA1 is thought to modulate transcription by influencing chromatin remodeling (Toh et al., 1994; Kumar et al., 2003) . Indeed, MTA1 is overexpressed in a variety of human cancers including cancers of the breast, ovary, lung, gastrointestinal system and colorectum (Toh et al., 1994 (Toh et al., , 1999 Hamatsu et al., 2003; Balasenthil et al., 2006; Jang et al., 2006; Martin et al., 2006) . It also plays an important role in metastasis and tumor aggressiveness (Toh et al., 1994 (Toh et al., , 1999 Jang et al., 2006) .
Another equally important gene that has long been implicated in metastasis is BRCA1. A large body of evidence shows a strong correlation between BRCA1 downregulation or dysfunction and increased metastasis. BRCA1, the first breast and ovarian cancer susceptibility gene, was identified in 1994 and since then, significant progress has been made toward the understanding of its functions in cells. BRCA1 is an important regulatory protein. It is involved in the regulation of the cell cycle, DNA damage repair, transcription and chromatin remodeling (Starita and Parvin, 2003; Deng, 2006; Ko et al., 2006; Mullan et al., 2006; Rosen et al., 2006; Yarden and Papa, 2006) . Recent evidence revealed a role of BRCA1 in the regulation of numeral homeostasis of centrosomes (Indraccolo et al., 2006; Ouchi, 2006) . Breast cancer occurs in both familial and sporadic forms. Mutations in BRCA1 account for about 10-15% of familial breast cancers; however, the role of BRCA1 in sporadic breast cancer has been ambiguous. Although hyper-methylation and loss of heterozygosity on chromosome 17 has been associated with sporadic breast cancer, very little is known about BRCA1's transcriptional repression (Turner et al., 2007) . Recent data suggest that the Ets-2 transcription factor may play a role in the repression of the BRCA1 promoter (Baker et al., 2003) . The notion that MTA1 might be a corepressor was merely speculative until the recent discovery that MTA1 associates with histone deacetylases (HDACs) and thereby helps to repress estrogen receptor-a (ERa) transactivation in breast cancer cells (Mazumdar et al., 2001; Talukder et al., 2003) . Since the BRCA1 promoter contains an atypical estrogen-responsive element (ERE) (Xu et al., 1997) , we hypothesized that MTA1 might play a role in BRCA1 repression. To test this, we addressed the mechanism for BRCA1 repression by MTA1 and further evaluated the mechanistic link, if any, between MTA1-mediated BRCA1 repression and centrosome number amplification in breast cancer cells. We identified centrosome amplification in MTA1-overexpressing cells and used centrosome number amplification as a functional marker of MTA1-mediated BRCA1 repression.
Results

MTA1 overexpression represses BRCA1 gene transcription
We used MTA1 overexpressing MCF7 cells as a model system to evaluate the effect of MTA1 on the status of BRCA1 and its downstream target poly-ADP-ribosepolymerase 1 (PARP1) (Simbulan-Rosenthal et al., 2001; Kanai et al., 2003) . By reverse transcriptase PCR (RT-PCR) analysis, we found that both BRCA1 and PARP1 were reduced at the mRNA level in MTA1-overexpressing cells when compared with control vectortransfected cells (Figure 1a ). To confirm this, northern blot analysis was conducted in MCF7/pcDNA and MCF7/MTA1 stable cells. BRCA1 mRNA levels were found to be downregulated in the MCF7/MTA1 cells ( Figure 1b) . A concomitant reduction of the protein levels of BRCA1 and PARP1 in MCF7/MTA1 clones was seen by western blotting analysis (Figure 1c) . Together, these results suggested that MTA1 overexpression repressed BRCA1 transcription. This notion was confirmed by knockdown of endogenous MTA1 by MTA1-specific RNA interference (RNAi) in MCF-7 cells, resulting in increased levels of BRCA1 protein (Figure 1d ). Together, these findings established an inverse correlation between MTA1 and BRCA1 expression in cancer cells.
MTA1 represses BRCA1 transcription
Using a pGL3-BRCA1 promoter (1-2696)-reporter system that includes one atypical ERE site (Figure 2a) , we showed that transient co-transfection of MTA1 significantly reduced the amount of transcription driven by a BRCA1-luc reporter. In MCF7, ZR75 and HC11 cells (ERa and ERb-positive, Supplementary Figure 1) . BRCA1 transcription was repressed by approximately 40% upon MTA1 overexpression (Figure 2b ). However, no inhibitory effect of MTA1 on BRCA1-reporter activity was noted either in an ERb-positive cell line (HSY cells) or in an ERa-and ERb-negative line (HeLa cells, Figure 2c ). Together, these findings suggested that MTA1 overexpression repressed BRCA1 transcription via ERa. Using a pGL3-BRCA1 promoter we showed that both MCF7/pcDNA and MCF7/MTA1 cells were able to induce BRCA1 expression on estradiol (E2) treatment. However, in comparison with the MCF7/ pcDNA control cells, MTA1 overexpression was able to repress BRCA1 expression under conditions of both presence and absence of E2 (Supplementary Figure 2) . Thus suggesting, MTA1-mediated repression of BRCA1 was E2-independent.
MTA1-NuRD complex associates with an ERE in the BRCA1 promoter To study the mechanism of BRCA1 repression in the presence of MTA1, we hypothesized that ERa may be recruiting MTA1 to the promoter via the E2-responsive element. To test this hypothesis, we conducted chromatin immunoprecipitation (ChIP) assays in MCF7/pcDNA and MCF7/MTA1 clones using a T7-tag-specific antibody. MTA1 clearly associated with the 200-bp region of the promoter containing the ERE. An aliquot of the same ChIP elute was used to PCR amplify the phosphofructokinase-muscle-type isoform (PFK-M) gene (Figure 3a) . Band for PFK-M gene in the input samples and no band in T7-ChIP samples demonstrated specific association of MTA1 to the BRCA1 promoter which inturn may explain the noted repression of MTA1-mediated regulation of BRCA1 transcription PR Molli et al BRCA1 in MTA1 overexpressing cells. The recruitment of MTA1-containing NuRD complex to the BRCA1 promoter was subsequently confirmed by sequential double ChIP assays in MCF7/pcDNA and MCF7/ MTA1 clones, first with an anti-T7-Mab to immunoprecipitate T7-MTA1 and then with an HDAC2 antibody. We found that indeed, MTA1-HDAC complex was recruited to the BRCA1 promoter in MCF7/MTA1 cells ( Figure 3b ). Moreover, treatment of MCF7/MTA1 cells with the HDAC inhibitor TSA increased BRCA1 expression at both the mRNA and protein levels, as demonstrated by RT-PCR and Western blot analysis, respectively ( Figure 3c ). Using BRCA1-luc-reporter assays, the repression of BRCA1 transcription in MCF7/MTA1 cells relative to pcDNA-transfected control cells was partially relieved by TSA treatment (Figure 3d ). In addition, ZR75 cells transiently transfected with pcDNA or MTA showed complete relief of repression of BRCA1 transcription on TSA treatment ( Figure 3e ). Together, these studies provided strong support to the association of the MTA1-NuRD complex to the BRCA1 promoter.
Role of ERa in association of MTA1-NuRD complex with the ERE in BRCA1 promoter
ChIP assays demonstrated MTA1's recruitment to the BRCA1 promoter was dependent on ERa. As shown in Figure 4c) . Similarly, the repression of BRCA1 transcription was relieved on ICI treatment using BRCA1-luc reporter assay (Figure 4d) . Together, these results demonstrated ERa-mediated recruitment of the MTA1-NuRD complex to the ERE on the BRCA1 promoter led to BRCA1 repression.
Co-operation between MTA1 and ERa in the regulation of BRCA1 repression To study the effect of ERa on BRCA1 gene expression, we silenced ERa expression in both MCF7 and HC11 cells using ERa-specific RNAi and examined expression of BRCA1 using BRCA1-luc reporter assay. BRCA1 MTA1-mediated regulation of BRCA1 transcription PR Molli et al levels increased when ERa expression was knockeddown (Figures 5a and b) . Western blot of the TCA precipitated luciferase cell lysate with ERa antibody confirmed the successful knocking down of ERa by the RNAi used. The same blot when probed for MTA1 showed almost equal levels of MTA1 in both the control and ERa knockdown samples thus confirming the role of ERa in MTA1-HDAC-mediated BRCA1 repression. We next silenced MTA1 in ERa-transfected HeLa cells using MTA1-specific RNAi and examined BRCA1 expression using BRCA1-luc reporter assay. Knocking down of MTA1 resulted in increased BRCA1 expression compared to that in the control cells (Figure 5c ). Western blot of the TCA precipitated luciferase cell lysate with MTA1 antibody confirmed the successful knocking down of MTA1 by the RNAi used. To validate the role of EREs in MTA1-mediated BRCA1 repression, we sequentially mutated the EREs on BRCA1 promoter using site-directed mutagenesis. Mutation of the ERE-1 region continued to show MTA1-mediated repression of BRCA1, probably because of the remaining ERE-2 and ERE-3 regions capable of recruiting MTA1 on BRCA1 promoter. However, simultaneous mutation of ERE-1 and ERE-2 was able to partially block MTA1-mediated BRCA1 repression and mutation of all the EREs-ERE-1 þ ERE-2 þ ERE-3 regions completely blocked MTA1-mediated BRCA1 repression (Figure 5d ). This indicated that MTA1-mediated repression of BRCA1 is via the sites marked as ERE-2 and ERE-3 and not by ERE-1 in the BRCA1 promoter.
To further confirm the involvement of ERa in recruiting MTA1 to the BRCA1 promoter, we checked the association of MTA1 to the BRCA1 promoter by ChIP assay under conditions of depleted ERa levels using ERa-specific RNAi. Results showed a loss of association of MTA1 to the BRCA1 promoter (Figure 5e (Figure 5f ).
MTA1 overexpression leads to generation of multiple spindle poles
Large body of evidence shows that cells on BRCA1 suppression exhibit increased number of centrosomes and eventually develop genomic instability. To explore if MTA overexpression had any effect on centrosome amplification, we used stable cell lines overexpressing MTA1, that is, MCF7 and HC11 cells (Figure 6a ). Similar to MCF7/MTA1 stable cells, overexpression of MTA1 in HC11 cells led to BRCA1 repression ( Figure 6a ). Both MCF7 and HCll cells were synchronized using double thymidine block and immunostained with antibody to a-tubulin and pericentrin (Figure 6b ). Pericentrin localization was used as an indicator of centrosomes. A total of 100 cells were counted in five different fields for each cell line and classified by centrosome number (that is, 1 or 2, X3 or abnormal spindle) (Figure 6c ). Careful analysis of these findings revealed a correlation between having high levels of MTA1 and centrosomal amplification. This finding implicated a mechanistic link between MTA1-mediated BRCA1 repression and centrosome number amplification in MTA1 overexpressing cells.
Reintroduction of BRCA1 into MTA1-overexpressing cells compromises abnormal centrosome number phenotype
In the light of our findings, we hypothesized that if centrosome accumulation in MTA1-overexpressing cells were due to BRCA1 repression, then reintroduction of BRCA1 would compromise the abnormal phenotype, at least partially. To test this hypothesis, MCF7/MTA1 stable cells were transfected either with GFP vector or with GFP-BRCA1 (Figure 7a ). Cells were immunostained with antibody to a-tubulin and pericentrin and with DAPI to visualize DNA. A total of 100 cells were counted in five different fields for each cell line and 
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classified by centrosome number (that is, 1, 2 or X3 centrosomes). MTA1 overexpressing cells transfected with GFP control vector continued to exhibit the increase in number of cells with abnormal centrosome amplification. However, just as we hypothesized, reintroducing BRCA1 into MTA1 overexpressing cells compromised the abnormal phenotype, thus implicating BRCA1 in MTA1-mediated centrosome amplification (Figure 7b ).
Discussion
The transformation of a normal cell into a malignant cancerous cell involves profound alterations in the cellular physiology leading to the appearance of distinct characteristics including anchorage-independent growth, immortalization and chromosomal instability. A major focus of research in cancer biology is directed at deciphering molecular mechanisms responsible for these MTA1-mediated regulation of BRCA1 transcription PR Molli et al malignant transformations. Numerous tissue-and cancer-type-specific genes have been identified whose mutation or abnormal transcription (or both) results in drastic changes in cellular function that ultimately promote cancerous transformations. One such gene, the tumor suppressor gene BRCA1, has been implicated in breast cancer. This is evident by the fact that half of all familial breast cancers, which represents 10% of the total breast cancers, BRCA1 protein function is impaired as a result of germline mutations in the gene (Fukasawa, 2005; Deng, 2006) . On the other hand, the remaining 90% of breast cancers occur sporadically in the absence of any apparent genetic predisposition. In these nonfamilial cases, tumorigenesis is likely not due to mutation but rather to a drastic decrease of BRCA1 mRNA or protein levels (Magdinier et al., 1998; Rio et al., 1999) . Multiple studies have shown a correlation between loss of BRCA1 expression and increased metastatic disease. In the light of these findings and because MTA1 is widely overexpressed in human cancers including breast cancer (Toh et al., 1994; Nawa et al., 2000; Jang et al., 2006) , and its overexpression has been associated with metastasis, it appears that the MTA1-containing NuRD complex exerts a repressive effect on BRCA1 expression. Consistent with this notion was the relatively significant decrease in the mRNA and protein levels of BRCA1 and its target PARP1 that we observed in MCF7/MTA1 stable cells stably when compared with control MCF7/pcDNA cells (Figure 1) . Previously, MTA1 has been shown to inhibit the expression of estrogen-responsive genes by repressing the transactivating functions of ERa (Mazumdar et al., 2001) . In addition, BRCA1 is itself an estrogenresponsive gene whose promoter contains an atypical ERE (Figure 2a ; Xu et al., 1997) . These observations point to the possibility that MTA1 might be recruited to (Figures 2b and c) . This provided an additional proof of dependency on ERa for the repressive effect of MTA1 on BRCA1 transcription. ChIP analysis provided further proof of the physical association of MTA1-NuRD complex with the ERE in BRCA1 promoter and thus, validating MTA1 as an effective corepressor of BRCA1 transcription (Figures 3a and b ). An enhancement in BRCA1 levels on treatment with HDAC inhibitor TSA (Figures 3c-e) and by MTA1 silencing (Figures 1d and 5c ), further validated an inverse mechanistic link between the levels of MTA1 and BRCA1. Consistent with the above findings, ChIP analysis showed a simultaneous association of ERa and MTA1 on the BRCA1 promoter (Figure 4a ) demonstrating an association of MTA1 to the ERE in BRCA1 promoter via ERa. Recruitment of MTA1 to BRCA1 promoter only in ERa-positive (MCF7) cells and not in ERa-negative (HeLa) cells, in spite of comparative higher levels of MTA1 in HeLa (Figure 4b ) and the loss of this recruitment in MCF7 cells on treatment with ICI, or under conditions of ERa depletion using siRNA to ERa, demonstrated the absolute dependency of this recruitment on ERa (Figures 4c, d and 5e).
One way in which the BRCA1 protein exerts its tumor suppressor function is by regulating the centrosomal number. Functional deregulation and centrosome amplification which leads to abnormal spindle formation and chromosomal instability is strongly associated with tumorigenesis (Fukasawa et al., 1996; D'Assoro et al., 2002) . Studies have shown that BRCA1 localizes to the centrosome and binds to g-tubulin, a major component of centrosomes (Starita et al., 2004) . In addition, BRCA1 has been shown to interact with a variety of proteins that regulate centrosome duplication like BRCA2, BubR1, CDK2-cyclin A, CDK2-cyclin E, Gadd45, p21, p53 and Rb) (Weaver et al., 2002; Chabalier et al., 2006) . This role has been confirmed in experiments in which embryonic fibroblasts derived from wild-type BRCA1-deficient mice showed amplified centrosome numbers. Centrosomal amplification is known to be a hallmark of cells whose BRCA1 expression or function has been disrupted (Weaver et al., 2002; Birgisdottir et al., 2006; Chen et al., 2006) . Interestingly, we observed a similar phenomenon of centrosomal amplification in MTA1 overexpressing cells (Figure 6b ). That normal centrosomal numbers could be restored by overexpression of BRCA1 in cells stably overexpressing MTA1 provided evidence that abnormal centrosomal amplification may be due to the drastic suppression of BRCA1 gene transcription (Figure 7a ).
In conclusion, our present studies have demonstrated that MTA1, a protein involved in nucleosomal remodeling and transcriptional repression, drastically repressed transcription of the BRCA1 gene by associating, via ERa, with the previously identified ERE in the BRCA1 gene promoter. As a consequence, cells overexpressing MTA1 exhibit centrosomal amplification, a phenomenon routinely observed in cells that have lost BRCA1 expression or functions. Although the role played by MTA1 in aggressive and metastatic cancers has been well established, its exact molecular mechanisms and gene targets have yet to be deciphered. Here, we have identified the BRCA1 gene as one of the gene targets 
Materials and methods
Cell culture and reagents MCF7, HeLa, HSY and HC11 cells were obtained from various sources and were cultured as described in Supplementary methods. Antibodies and other reagents used in the study were purchased from companies as described in Supplementary methods.
Generation of stable clones
The stable clones of MTA1 or pcDNA in MCF7 cells and HC11 cells were generated as mentioned elsewhere (Mazumdar et al., 2001; Bagheri-Yarmand et al., 2004) . Transient transfection of MCF7/MTA1 cells was performed as described in Supplementary methods.
Immunofluorescence and confocal microscopy Cells were grown on glass coverslips, fixed and stained as described in Supplementary methods.
RT-PCR analysis RNA was extracted from cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and PCR amplifications were performed as described in the Supplementary methods.
Northern blot analysis
Total RNA was extracted from MCF7/pcDNA and MCF7/ MTA1 cells using Trizol reagent and a northern blot was performed as described in Supplementary methods.
siRNA transfection and MTA1 or ERa knockdown analysis
Small interfering RNA (siRNA) against human MTA1 or human ERa was purchased from Dharmacon (Lafayette, CA, USA). Cells were transfected as described in Supplementary methods.
Luciferase reporter assay
Cells were seeded on six-well tissue culture plates and post 24 h, they were transfected with pGL3 control or pGL3
BRCA1 promoter luciferase using FuGENE 6 transfection reagent (Roche Applied Science, Indianapolis, IN, USA). Luciferase activity was assayed 48 h later using a luciferase assay kit (Promega, Madison, WI, USA).
Site-directed mutagenesis BRCA1-ERE mutants were generated using a QuikChange kit (Stratagene, La Jolla, CA, USA), using pGL3 basic BRCA1 promoter as template. The primers used are described in Supplementary methods.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed as described previously (Mazumdar et al., 2001) . DNA extracted was subjected to PCR analysis as described in the Supplementary methods.
Immunoblot analysis
Cells from stable clones were grown in complete medium. When indicated, TSA was added to the culture medium and the cells were incubated at 37 1C for 16 h. Protein extracts were made and western blotting was performed as described in the Supplementary methods.
Statistical analysis
Statistical analyses were performed using SPSS version 11.0 software. The samples were analysed using two-sided Student's t-test. P values o0.05 were considered significant.
Abbreviations
BRCA1, breast cancer susceptibility gene 1; ChIP, chromatin immunoprecipitation; ERa, estrogen receptor a; ERE, estrogen-responsive element; HDAC, histone deacetylase; MTA1, metastasis-tumor antigen 1; NuRD complex, nucleosome remodeling and deacetylase complex; TSA, trichostatin A.
